Listed

Northwest Biotherapeutics Inc

NWBOOTCCIK 1072379HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$807.0kRevenue, Q2 FY2026, three months to 2026-06-30$807.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 14, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$807.0kRevenue, Q2 FY2026, three months to 2026-06-30$807.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure+516.0% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−1438.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$11.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Revenue: $807.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure+9843.6 pts on a year earlier
  • Net margin−1142.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Revenue: $807.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure+10596.3 pts on a year earlier
  • Diluted EPS−$0.01Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure+0.0% on a year earlier
  • Free cash flow−$7.4mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Capital expenditure: $198.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Report this figure−5.4% on a year earlier

Last eight quarters

Full statements
Revenue$807.0kOperating margin −1438.0%
Diluted EPS−$0.01, Q2 FY2026
Free cash flow−$7.4m, Q2 FY2026
Northwest Biotherapeutics Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m0.4Revenue, Q3 FY2024, three months to 2024-09-30$357.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure0.2Revenue, Q4 FY2024, three months to 2024-12-31$231.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure0.4Revenue, Q1 FY2025, three months to 2025-03-31$375.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure0.1Revenue, Q2 FY2025, three months to 2025-06-30$131.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure0.2Revenue, Q3 FY2025, three months to 2025-09-30$200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure0.7Revenue, Q4 FY2025, three months to 2025-12-31$672.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure0.5Revenue, Q1 FY2026, three months to 2026-03-31$494.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure0.8Revenue, Q2 FY2026, three months to 2026-06-30$807.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(4145.9%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$14.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Revenue: $357.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(8008.2%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$18.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Revenue: $231.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(4616.3%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$17.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Revenue: $375.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(11281.7%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$14.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Revenue: $131.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(7160.0%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$14.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Revenue: $200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(2009.5%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$13.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Revenue: $672.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(2206.5%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$10.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Revenue: $494.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(1438.0%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$11.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Revenue: $807.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Net margin%(5426.9%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$19.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Revenue: $357.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure(12217.7%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$28.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Revenue: $231.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(5158.1%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$19.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Revenue: $375.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(11738.9%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$15.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Revenue: $131.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(13414.5%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Revenue: $200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figure206.5%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Revenue: $672.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(621.3%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$3.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Revenue: $494.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(1142.6%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Revenue: $807.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Diluted EPS$ per share(0.02)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figurenot reported (Diluted EPS not reported)(0.01)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(0.01)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure(0.02)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001104659-25-112676.Report this figurenot reported (Diluted EPS not reported)0.00Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(0.01)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097188.Report this figure
Free cash flow$m(8.4)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$8.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001104659-25-112676. Derived: 9-month figure less the 6-month figure.Capital expenditure: $176.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001104659-25-112676. Derived: 9-month figure less the 6-month figure.Report this figure(20.3)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$20.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Capital expenditure: $78.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(9.5)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$9.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Capital expenditure: $93.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(7.0)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Capital expenditure: $304.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Report this figure(14.1)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$13.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001104659-25-112676. Derived: 9-month figure less the 6-month figure.Capital expenditure: $202.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001104659-25-112676. Derived: 9-month figure less the 6-month figure.Report this figure(15.7)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$14.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Capital expenditure: $905.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-15, accession 0001104659-26-043806. Derived: 12-month figure less the 9-month figure.Report this figure(12.6)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$12.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Capital expenditure: $129.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001104659-26-062661.Report this figure(7.4)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Capital expenditure: $198.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001104659-26-097188. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.4mOperating margin −4347.9%
Diluted EPS−$0.04, FY2025
Free cash flow−$46.3m, FY2025
Northwest Biotherapeutics Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m1.0Revenue, FY2021, twelve months to 2021-12-31$1.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-05, accession 0001410578-24-000133.Report this figure1.7Revenue, FY2022, twelve months to 2022-12-31$1.7m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-05, accession 0001410578-24-000133.Report this figure1.9Revenue, FY2023, twelve months to 2023-12-31$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure1.4Revenue, FY2024, twelve months to 2024-12-31$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure1.4Revenue, FY2025, twelve months to 2025-12-31$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(5244.0%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$52.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-05, accession 0001410578-24-000133.Revenue: $1.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-05, accession 0001410578-24-000133.Report this figure(3991.7%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$67.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-05, accession 0001410578-24-000133.Revenue: $1.7m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-05, accession 0001410578-24-000133.Report this figure(2873.1%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$55.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001410578-25-000598.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure(4812.4%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$66.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure(4347.9%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$59.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure
Net margin%17823.5%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $179.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-05, accession 0001410578-24-000133.Revenue: $1.0m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-05, accession 0001410578-24-000133.Report this figure(6240.8%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$105.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-05, accession 0001410578-24-000133.Revenue: $1.7m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-05, accession 0001410578-24-000133.Report this figure(3240.1%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$62.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001410578-25-000598.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure(6062.1%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$83.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure(4365.9%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$60.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043806.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure
Diluted EPS$ per share(0.06)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-05, accession 0001410578-24-000133.Report this figure(0.10)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-05, accession 0001410578-24-000133.Report this figure(0.06)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-31, accession 0001410578-25-000598.Report this figure(0.07)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure(0.04)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(58.0)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$57.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043806.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure(46.3)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$44.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043806.Capital expenditure: $1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-15, accession 0001104659-26-043806.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Northwest Biotherapeutics Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
COMPASS FINANCIAL MANAGEMENT LLC2026-06-30$227.1k1,215,500Not compared
KELLEHER FINANCIAL ADVISORS2026-06-30$149.4k800,000Added+600,000
VSM Wealth Advisory, LLC2026-06-30$15.1k80,574Unchanged
Ethos Financial Group, LLC2026-06-30$6.3k39,070Unchanged
Williams Jones Wealth Management, LLC.2026-06-30$4.7k25,000Unchanged
McIlrath & Eck, LLC2026-03-31$124600Not compared
Opus Capital Group, LLC2026-06-30$1160,150Unchanged
HANTZ FINANCIAL SERVICES, INC.2026-06-30$0250Unchanged
Coston, McIsaac & Partners2026-06-30$01,000Unchanged

Recent filings

All 600 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Northwest Biotherapeutics Inc, recent filings
FiledFormWhat it isAccession number
2026-08-1416:17 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-097188
2026-07-3117:17 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation0001104659-26-089293
2026-07-2019:48 ET8-K7.01 Regulation FD disclosure0001104659-26-084743
2026-05-1516:34 ET10-QQuarterly reportPeriod 2026-03-310001104659-26-062661
2026-04-1516:16 ET10-KAnnual reportPeriod 2025-12-310001104659-26-043806
2026-04-0712:30 ET8-K2.01 Completion of an acquisition or disposition0001104659-26-040260
2026-01-1517:06 ET8-K8.01 Other events0001104659-26-004146
2026-01-0217:14 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-26-000243
2025-11-2816:43 ETDEF 14AProxy statementPeriod 2025-12-290001104659-25-116966
2025-11-2016:26 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation0001104659-25-114627

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Apr 15, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1072379
Tickers
NWBO
Exchange
OTC
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:32 ET. Listed shows no prices and gives no investment advice.